On June 26, 2025, Biogen (BIIB, Financial) received reaffirmation from HC Wainwright & Co. analyst Andrew Fein, who reiterated a "Buy" rating on the stock. The analyst maintained the price target at USD 187.00, unchanged from the prior target. This decision reflects steadiness in the analyst's outlook on Biogen's future performance.
The current analysis does not represent any percentage change in the price target, as the previous and current price targets remain consistent at USD 187.00. Biogen (BIIB, Financial) continues to be seen as a strong opportunity by Andrew Fein, supporting ongoing investor confidence in the biotechnology company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $169.94 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 33.49% from the current price of $127.31. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.20, suggesting a upside of 65.89% from the current price of $127.31. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
